Patents Assigned to SEAGEN INC.
  • Publication number: 20240173427
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to GPC3 and conjugates thereof.
    Type: Application
    Filed: October 13, 2023
    Publication date: May 30, 2024
    Applicant: SEAGEN INC.
    Inventors: Travis Biechele, William Arthur, Patrick Burke, Lori Westendorf
  • Publication number: 20240165229
    Abstract: The invention provides methods of treating cancer, such as myeloid malignancies including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), with a nonfucosylated anti-CD70 antibody in combination with a CD47 antagonist.
    Type: Application
    Filed: June 28, 2022
    Publication date: May 23, 2024
    Applicant: SEAGEN INC.
    Inventors: Daniel Diolaiti, Shyra Gardai
  • Publication number: 20240109975
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Application
    Filed: August 15, 2023
    Publication date: April 4, 2024
    Applicant: SEAGEN INC.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • Patent number: 11944689
    Abstract: Compounds and compositions are disclosed in which a Drug Unit is linked to a targeting Ligand Unit through a self-stabilizing Linker Unit from which a drug compound or active drug moiety is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: April 2, 2024
    Assignee: Seagen Inc.
    Inventor: Philip Moquist
  • Patent number: 11938194
    Abstract: The invention provides modified heavy chain constant regions including a cysteine at position 295 by EU numbering and optionally at position 239 by EU numbering. These cysteine residues provide sites for conjugation to a drug or label. When both cysteines are present in a normal heterodimeric antibody format, there are four such sites per molecule of antibody allowing a stoichiometry of one molecule of antibody to four of drug or label. Selection of the cysteine at position 295 with or without cysteine at position 239 is advantageous over cysteines at many other positions due to ease of expression, stability and cytotoxicity.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: March 26, 2024
    Assignee: SEAGEN INC.
    Inventors: Andrew Waight, Chris Leiske, Travis Biechele, Django Sussman, Patrick Burke, Jocelyn Leiske
  • Patent number: 11931414
    Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is conjugated to a targeting Ligand Unit through quaternization by a Linker Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as those of cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 19, 2024
    Assignee: Seagen Inc.
    Inventors: Christopher Scott Neumann, Kathleen Olivas, Robert Lyon, Kung-Pern Wang
  • Publication number: 20240084031
    Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.
    Type: Application
    Filed: December 5, 2022
    Publication date: March 14, 2024
    Applicant: Seagen Inc.
    Inventors: Paul Carter, Django Sussman
  • Publication number: 20240076383
    Abstract: Provided are novel anti-av?6 antibodies and antibody-drug conjugates and methods of using such anti-av?6 antibodies and antibody-drug conjugates to treat cancer.
    Type: Application
    Filed: October 18, 2023
    Publication date: March 7, 2024
    Applicant: SEAGEN INC.
    Inventors: Maureen Ryan, Lori Westendorf, Eric Bradley Meyer, Heather Jean Kostner
  • Publication number: 20240043556
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: March 10, 2023
    Publication date: February 8, 2024
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventors: Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
  • Patent number: 11891644
    Abstract: Methods of producing T cells having reduced surface fucosylation and use thereof in adoptive cell therapy, in particular, in cancer treatment are provided.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: February 6, 2024
    Assignee: Seagen Inc.
    Inventors: Nicole Okeley, Jessica Field, Shyra Gardai, Ryan Heiser
  • Publication number: 20240025998
    Abstract: Provided herein are methods of treating cancer with an anti-TIGIT antibody in combination with an anti-PD-1 antibody and/or an anti-PD-L1 antibody.
    Type: Application
    Filed: September 29, 2023
    Publication date: January 25, 2024
    Applicant: Seagen Inc.
    Inventors: Shyra Gardai, Alyson Smith
  • Publication number: 20240009306
    Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. In some embodiments, the present invention provides an antibody having a heavy chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 63 and having a light chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 64.
    Type: Application
    Filed: November 7, 2022
    Publication date: January 11, 2024
    Applicant: Seagen Inc.
    Inventors: Ana Paula Galvao da Silva, Julie DeSander, Jeffrey Behrens, Darius Ghaderi, Mai Zhang, Kristan Meetze
  • Publication number: 20240002537
    Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.
    Type: Application
    Filed: November 7, 2022
    Publication date: January 4, 2024
    Applicants: Seagen Inc., The General Hospital Corporation
    Inventors: David A. Eavarone, Jeffrey Behrens, Jillian M. Prendergast, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
  • Publication number: 20240002422
    Abstract: The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.
    Type: Application
    Filed: February 28, 2023
    Publication date: January 4, 2024
    Applicant: Seagen Inc.
    Inventors: Ana Paula Galvao da Silva, Mai Zhang, Darius Ghaderi, Julie DeSander, Jeffrey Behrens, Jillian M. Prendergast
  • Publication number: 20240003889
    Abstract: The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.
    Type: Application
    Filed: November 7, 2022
    Publication date: January 4, 2024
    Applicants: Seagen Inc., The General Hospital Corporation
    Inventors: David A. Eavarone, Julie DeSander, Jeffrey Behrens, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
  • Publication number: 20240000962
    Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.
    Type: Application
    Filed: November 7, 2022
    Publication date: January 4, 2024
    Applicant: Seagen Inc.
    Inventors: Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
  • Patent number: 11857565
    Abstract: Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities towards nearby cells having lower expression of the moeity targeted by the Conjugate.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: January 2, 2024
    Assignee: SEAGEN INC.
    Inventors: Svetlana O. Doronina, Philip Moquist
  • Patent number: 11844839
    Abstract: The present invention provides improved processes for the preparation of auristatin drug-linkers with a PEG unit, as well as intermediates thereof.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: December 19, 2023
    Assignee: Seagen Inc.
    Inventors: Yunyu Mao, Philip Moquist, Anusuya Choudhury, Wendel Doubleday
  • Patent number: 11827709
    Abstract: Provided are novel anti-?v?6 antibodies and antibody-drug conjugates and methods of using such anti-?v?6 antibodies and antibody-drug conjugates to treat cancer.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: November 28, 2023
    Assignee: Seagen Inc.
    Inventors: Maureen Ryan, Lori Westendorf, Eric Bradley Meyer, Heather Jean Kostner
  • Patent number: 11819553
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to GPC3 and conjugates thereof.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: November 21, 2023
    Assignee: Seagen Inc.
    Inventors: Travis Biechele, William Arthur, Patrick Burke, Lori Westendorf